Spots Global Cancer Trial Database for Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Official Title: A Phase 1 Dose-escalation Study of PSMA ADC in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer
Study ID: NCT01414283
Conditions
Interventions
Study Description
Brief Summary: Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. For all subjects, PSMA ADC will be administered in four repeating cycles.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Contact Details
Name: Robert J Israel, MD
Affiliation: Progenics Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
